reports
Result of Extraordinary General Meeting and Delisting from Euronext Am...
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI, (“BenevolentAI” or “the Company”) (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that: All resolutions proposed at its Extraordinary General Meeting held today (the “EGM”) were duly passed with overwhelming support (over 95% in favour). Effective immediately, BenevolentAI has merged into Osaka Holdings S.à r.l. (“Osaka Holdings”). As a result, the original BenevolentAI entity has ceased to exist. Simultaneously, Osaka Holdings has converted its legal form from an S.à r.l. to an S.A., and has adop...
Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à ...
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI, (“BenevolentAI” or “the Company”) (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces: Subject to shareholder approval, the proposed delisting of BenevolentAI from Euronext Amsterdam N.V. (the “Delisting”) via a merger of the Company into Osaka Holdings S.à r.l. (“Osaka Holdings”), (the “Merger”), which will transition the Company to a private company structure. Simplification of the Company’s share structure and related instruments that reduces the current complexity and administrative overheads. ...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: January 2025
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
- Martin Hall
Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
SNG SYNAIRGEN PLC
IPO IP GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
TXG 10X GENOMICS INC CLASS A
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
Z29 TISSUE REGENIX GROUP PLC
029 GROUP SE
BenevolentAI Unveils Major Strategic Overhaul With Return to Original ...
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (“the Company”), a pioneer in integrating artificial intelligence with biopharmaceutical development, today unveils a major strategic overhaul to return the Company to its founding TechBio mission. These changes mark a return to the Company’s foundational strengths, refocusing efforts on core technologies and innovation to better develop transformative drug discovery and development solutions. In parallel, and to support this, the Company has initiated significant organisational and budgetary changes that extend the Company’s runway int...
BenevolentAI Appoints Kenneth Mulvany as Executive Chairman
LONDON--(BUSINESS WIRE)-- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery and development, today announces the appointment of Kenneth (Ken) Mulvany as Executive Chairman. Dr. Joerg Moeller is stepping down as Chief Executive Officer with immediate effect. Ken Mulvany, Executive Chairman of BenevolentAI commented: “When we founded BenevolentAI, our vision was to harness the power of AI to tackle healthcare's most pressing challenges. We have since developed one of the world's most advanced and val...
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTec...
LONDON--(BUSINESS WIRE)-- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology Officer, will hold a presentation titled "Building Trust and Explainability in using AI in Drug Discovery" at BioTechX Europe in Basel on 10 October 2024 at 11:45 AM CET. The presentation will discuss how explainable artificial intelligence can increase transparency in drug discovery, focusing on BenevolentAI's innovative R2E (Retrieve to Explain) system. At the event, Dr Ma...
- Damien Choplain
- Marc Lavaud
- Oussema Denguir
- Damien Choplain
- Marc Lavaud
- Oussema Denguir
ODDO BHF Small & MIDCAP MORNING NEWS - 09/20/2024
Tubacex is a solutions provider for the energy and mobility sectors through high value-added products (seamless stainless-steel tubes) and services. It has recently completed a successful transformation which should result in a much more stable results and cash flow profile going forward (EBITDA margin c.15% vs 10-year historical average of 9%) although 2024 will be a transition year ahead of the completion of the ADNOC contract and the closing of Mubadala’s transaction (acquisition o...
- Damien Choplain
- Oussema Denguir
BenevolentAI : H1 2024 results contained no surprises. Out-licensing o...
>Cost-cutting plan paying off - BenevolentAI released its H1 2024 results yesterday. Our key takeaways are as follows: 1/ revenues down 46% to £ 2.8m, marked both by lower revenues from the AstraZeneca collaboration and including receipts from the recent Merck collaboration, which are expected to grow over the H2 2024-2026 period, 2/ a 39% reduction in R&D expenditure to -£ 19.5m and 3/ a reduction in SG&A expenditure of 21% to -£ 10.3m, in line with the cost-cutting ...
- Damien Choplain
- Oussema Denguir
BenevolentAI : Résultats S1 2024 sans surprise. Out-licencing de BEN-8...
>Un plan de réduction des dépenses qui porte ses fruits - BenevolentAI a communiqué hier ses résultats du S1 24. Nous en soulignons les points suivants : 1/ des revenus en baisse de 46% à 2.8 M£ provenant de la collaboration avec AstraZeneca et incluant les encaissements issus de la récente collaboration avec Merck qui devraient progresser sur la période S2 2024 -2026, 2/ une diminution des dépenses R&D de 39% à 19.5 M£ et 3/ une réduction des dépenses SG&A de 21% à 1...
BenevolentAI Interim Results for the Six Months Ended 30 June 2024
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI ("BenevolentAI" or “the Company" or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2024. Peter Allen, Chair, said: “I was delighted to join the Board as Chair in May, along with the other new Non-Executive Directors, to support the leadership of the Company. BenevolentAI has consistently been a pioneer and leader in AI drug discovery and development, and we are committed to capitalising on the signi...
BenevolentAI: Appointment of Adviser
LONDON--(BUSINESS WIRE)-- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company’s Financial and Capital Markets Adviser, with immediate effect. Kenneth Mulvany, Deputy Chair of BenevolentAI, commented: “We are pleased to appoint Deutsche Numis as our UK and pan-European corporate broker. We look forward to working with their team to maximise our capital markets strategy and realise the true value in BenevolentAI.” Category: non-regulatory...
- Team Pharma
ODDO : The macroeconomic environment is not helping the sector
The last few weeks had seen renewed interest in the sector, with stronger volumes, M&A activity and market transactions. Unfortunately, the political context in France has again undermined French biotechs. A large number of clinical results are expected in the next few months (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax, etc.). If successful, these could reinvigorate the sector. In the meantime, we are taking a more decisive stance, increasing the beta of the firms in our sa...
- Team Pharma
ODDO : L'environnement macro ne favorise pas le secteur
Ces dernières semaines avaient laissé entrevoir un regain d’intérêt pour le secteur avec une hausse des volumes, du M&A et des opérations de marché. Malheureusement le contexte politique français vient à nouveau de pénaliser les biotechs françaises. Un nombre important de résultats cliniques sont attendus dans ces prochains mois (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax…) qui pourraient, en cas de succès, redynamiser le secteur. Dans l’intervalle, nous décidons d’être plu...
BenevolentAI: Leadership Team Change
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted ste...
BenevolentAI and AstraZeneca Collaboration Yields Continued Success as...
LONDON--(BUSINESS WIRE)-- BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI. Second target to be selected this year from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of target identification Novel target for SLE was discovered using BenevolentAI’s AI-drug discovery platform and ex...
BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Scien...
LONDON--(BUSINESS WIRE)-- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming Morgan Stanley 3rd Annual Life Sciences AI Summit, 26-27 June 2024, in New York, US. Dr Joerg Moeller MD, Chief Executive Officer, is scheduled to take part in the panel discussion ‘Value Creation with AI for Drug Discovery’ at 09:55 EDT (14:55 BST), 27 June 2024, moderated by Vikram Purohit, Executive Director & Equity Analyst, Morgan Stanley. Dr Moeller and memb...
BenevolentAI to participate in Goldman Sachs 45th Annual Global Health...
LONDON--(BUSINESS WIRE)-- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that it will participate in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, 11-13 June 2024 in Miami, US. Dr Joerg Moeller MD, Chief Executive Officer, and Catherine Isted ACMA, Chief Financial Officer, are scheduled to take part in a fireside chat at 08:40 EDT (13:40 BST) on 13 June 2024. They will also be available throughout the conference for meetings on-site and adjacent to the progra...
- Damien Choplain
- Oussema Denguir
BenevolentAI : En quête d’un nouveau souffle
La récente arrivée de la nouvelle équipe de management pourrait donner un nouveau souffle à la société qui a traversé une période marquée par l’échec clinique de son ancien produit phare BEN-2293. Nous avons ajusté notre modèle afin d’intégrer le nouveau plan de développement de la société faisant ressortir un OC à 0.9 €. Malgré un potentiel de hausse important, nous restons prudents à CT / MT dans l’attente d’avoir plus de données cliniques pour BEN-8744 actuellement en phase 1 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.